Massachusetts General Hospital (Boston) psychedelic research trials
Data as of 11 October 2026. Source: ClinicalTrials.gov records held by PsychoactiveMap, refreshed from a reviewed snapshot.
Massachusetts General Hospital is listed with 10 registered studies counted here, in Boston, United States. By compound: 10 ketamine. By registry status: 2 recruiting, 1 active, not recruiting, 3 completed, 2 terminated and 2 withdrawn. By phase: 1 phase 1, 1 phase 3, 3 phase 4 and 5 not applicable. Reported start years run from 2010 (earliest) to 2026 (latest).
Institution name, city and country are copied from the research site linked to each registry record. A study counts once per institution, and a study tagged with more than one compound is counted under each compound.
Educational information, not medical advice. A registry listing is not evidence of safety, benefit or results, and it is not a recommendation. PsychoactiveMap does not recruit, screen or refer participants. Status and other details are copied from the registry and can be out of date, so check the registry record and speak to a qualified health professional before any decision. Read the full disclaimer.
At a glance
- 10 registered studies are counted on this page.
By compound
| Compound hub | Studies |
|---|---|
| Ketamine | 10 |
By registry status
| Status | Studies | Share |
|---|---|---|
| Recruiting | 2 | 20% |
| Active, not recruiting | 1 | 10% |
| Completed | 3 | 30% |
| Terminated | 2 | 20% |
| Withdrawn | 2 | 20% |
By phase
| Phase | Studies | Share |
|---|---|---|
| Phase 1 | 1 | 10% |
| Phase 3 | 1 | 10% |
| Phase 4 | 3 | 30% |
| Not applicable | 5 | 50% |
Registered studies
All counted studies, newest start first. The order is not a ranking and says nothing about quality. Titles are quoted from the registry. Each ID links to its own ClinicalTrials.gov record, which has the eligibility criteria and contacts.
| Title as registered | Registry ID | Status | Phase | Start | Compound |
|---|---|---|---|---|---|
| Coaching as an Adjunct to Ketamine Therapy for Treatment-Resistant Depression | NCT07563868 | Recruiting | Not applicable | 2026-04-01 | Ketamine |
| Integrating Ketamine Effects on Neuronal Molecular Signatures and the Brain Functional and Structural Connectome | NCT06698848 | Active, not recruiting | Phase 1 | 2025-01-01 | Ketamine |
| Long-Term Maintenance With Ketamine and Esketamine for Reduction of Suicide in High-Risk Patients With Depression | NCT05450432 | Recruiting | Phase 4 | 2022-10-13 | Ketamine |
| The Impact of Ketamine on the Reward Circuitry of Suicidal Patients | NCT02532153 | Withdrawn | Phase 3 | 2017-02-01 | Ketamine |
| Physiological and Cognitive Biomarkers for Ketamine's Antidepressant Effects | NCT02669043 | Terminated | Not applicable | 2016-07-01 | Ketamine |
| Ketamine for Depression: An MRI Study | NCT02544607 | Completed | Phase 4 | 2016-03-01 | Ketamine |
| Ketamine and Scopolamine Infusions for Treatment-resistant Major Depressive Disorder | NCT01613820 | Withdrawn | Not applicable | 2015-09-01 | Ketamine |
| Ketamine Versus Placebo for Treatment Resistant Major Depressive Disorder | NCT01667926 | Completed | Not applicable | 2013-01-01 | Ketamine |
| Ketamine Infusion for Treatment-resistant Major Depressive Disorder | NCT01582945 | Completed | Not applicable | 2012-04-01 | Ketamine |
| N-methyl-D-aspartate Antagonist (Ketamine) Augmentation of Electroconvulsive Treatment for Severe Major Depression | NCT01260649 | Terminated | Phase 4 | 2010-11-01 | Ketamine |
About this data
Compound tags come from automated matching of the registry search term and have not been checked record by record. Counts are of registered studies, not of people, results or approvals. A registry listing is not evidence of safety, benefit or results.